Moors & Cabot’s AbbVie ABBV Stock Holding History

Moors & Cabot’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Hold	0	–	-$1.61K	–	845
2023 Q1	–	Sell	-500	Closed	-$76.4K	–	873
2022 Q4	$6.55K	Hold	500	–	–	﹤0.01%	832
2022 Q3	$2K	Buy	+500	New	+$71.7K	﹤0.01%	813
2020 Q3	–	Sell	-2,100	Closed	-$7K	–	708
2020 Q2	$7K	Buy	+2,100	New	+$185K	﹤0.01%	655
2019 Q4	–	Sell	-35,000	Closed	-$27K	–	621
2019 Q3	$27K	Buy	+35,000	New	+$2.4M	﹤0.01%	637
2016 Q1	–	Sell	-2,500	Closed	-$8K	–	522
2015 Q4	$8K	Hold	2,500	–	–	﹤0.01%	507
2015 Q3	$6K	Buy	+2,500	New	+$163K	﹤0.01%	502

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Moors & Cabot's ABBV Position: Q2 2026 in Review

Moors & Cabot increased its AbbVie (ABBV) stake by 0.61% in Q2 2026, buying an estimated $91.7K and bringing the position to 70,717 shares worth $17.8M. The position accounts for 0.69% of the portfolio, ranked #27.

Moors & Cabot first reported a position in ABBV in Q1 2014 and has held it in 50 quarters since. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Moors & Cabot held 70,717 shares of AbbVie worth $17.8M as of Q2 2026.
Moors & Cabot bought 426 AbbVie shares in Q2 2026, an estimated $91.7K.
AbbVie made up 0.69% of Moors & Cabot's portfolio in Q2 2026, its #27 holding.
Moors & Cabot first reported a position in AbbVie in Q1 2014 and has held it in 50 quarters since.
4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.